<p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p>北卡罗来纳州达勒姆，2026 年 6 月 10 日（全球新闻稿）—— Humacyte, Inc.（纳斯达克：HUMA）是一家商业阶段的生物技术平台公司，开发可普遍植入的生物工程人类组织，今天宣布以每股 1.05 美元的公开发行价格定价 47,619,048 股普通股的承销公开发行。预计此次发行的总毛收益为 5000 万美元，未扣除 Humacyte 应支付的承销折扣和佣金及其他发行费用。此次发行的结束预计将在 2026 年 6 月 12 日左右进行，具体取决于满足惯例的结束条件。此外，Humacyte 已向承销商授予 30 天的选择权，以按公开发行价格购买最多 7,142,857 股 Humacyte 的普通股，扣除承销折扣和佣金。所有普通股均由 Humacyte 出售。</p>
<p>巴克莱银行、BTIG 和 Titan Partners（美国资本合伙公司的一个部门）作为此次发行的联合账簿管理人。</p>
<p>Humacyte 打算将其从此次发行中获得的净收益用于资助 Symvess® 的商业化、计划提交生物制品许可证申请补充的血液透析适应症及相关活动、开发其管道中的产品候选者，以及用于营运资金和一般企业用途。</p>
<p>在 2025 年 9 月 12 日，已向证券交易委员会（“SEC”）提交了一份 S-3 表格的货架注册声明（编号 333-290231），并于 2025 年 9 月 22 日获得 SEC 的有效声明。证券是通过与此次发行相关的招股说明书补充和附带招股说明书进行发行的，这些文件构成注册声明的一部分。与此次发行相关的初步招股说明书补充及附带招股说明书已于 2026 年 6 月 10 日提交给 SEC，并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书补充及附带招股说明书将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。在投资此次发行之前，您应完整阅读与此次发行相关的每份招股说明书补充及附带招股说明书，以及 Humacyte 向 SEC 提交的其他文件，这些文件在招股说明书补充及附带招股说明书中引用，提供有关 Humacyte 和此次发行的更多信息。最终招股说明书补充的副本（可用时）及与此次发行相关的附带招股说明书可从巴克莱资本公司（Barclays Capital Inc.），邮寄地址：Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717，电话：(888) 603-5847，或通过电子邮件 barclaysprospectus@broadridge.com；BTIG, LLC，地址：65 East 55th Street, New York, New York 10022，电话：(212) 593-7555，或通过电子邮件 ProspectusDelivery@btig.com；或 Titan Partners Group LLC（美国资本合伙公司的一个部门），地址：4 World Trade Center, 49th Floor, New York, NY 10007，电话：(929) 833-1246，或通过电子邮件 prospectus@titanpartnersgrp.com 获取。</p>
<p>本新闻稿不构成出售或招揽购买此处所述任何证券的要约，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不符，则此类要约、招揽或销售将是非法的。</p>
<p><strong>关于 Humacyte</strong></p>
<p>Humacyte, Inc.（纳斯达克：HUMA）是一家商业阶段的生物技术平台公司，开发可普遍植入的生物工程人类组织，并于 2025 年第一季度开始在美国商业推出其首个 FDA 批准的产品 Symvess。Humacyte 正在开创可即用的、普遍植入的生物工程人类组织、先进组织构造和器官系统的开发与制造，旨在改善患者的生活并改变医学实践。Humacyte 正在利用其新颖、可扩展的技术平台，开发专有的生物工程无细胞人类组织，用于治疗多种解剖部位的疾病和病症，涵盖多个治疗领域。</p>
<p>除美国食品和药物管理局（“FDA”）在肢体血管创伤适应症下的批准外，无细胞组织工程血管（“ATEV”）为一种研究性产品，尚未获得 FDA 或任何其他监管机构的销售批准。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含基于信念和假设以及当前可用信息的前瞻性声明。在某些情况下，您可以通过以下词语识别前瞻性声明：“可能”、“将”、“能够”、“会”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“正在进行” 或这些术语的否定形式或其他可比术语，尽管并非所有前瞻性声明都包含这些词。这些声明涉及风险、不确定性和其他因素，可能导致实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的信息有实质性差异。尽管 Humacyte 相信其对本新闻稿中每个前瞻性声明都有合理的依据，但 Humacyte 提醒您，这些声明是基于其当前已知的事实和因素的组合以及对未来的预测，Humacyte 对此无法确定。本新闻稿中的前瞻性声明包括但不限于关于发行的惯常成交条件的时间和满足情况以及预计的发行收益使用情况的声明。Humacyte 无法保证本新闻稿中的前瞻性声明将被证明是准确的。这些前瞻性声明受到许多重大风险和不确定性的影响，这些风险和不确定性可能导致实际结果与预期结果有实质性差异，包括但不限于适用法律或法规的变化，Humacyte 可能受到其他经济、商业和/或竞争因素的不利影响的可能性，以及其他风险和不确定性，包括在 Humacyte 截至 2025 年 12 月 31 日的年度报告 Form 10-K 和截至 2026 年 3 月 31 日的季度报告 Form 10-Q 中描述的 “风险因素” 标题下的风险，这些报告均已由 Humacyte 提交给 SEC，以及未来的 SEC 文件。这些因素大多数超出了 Humacyte 的控制范围，且难以预测。此外，如果前瞻性声明被证明不准确，则不准确性可能是实质性的。鉴于这些前瞻性声明中的重大不确定性，您不应将这些声明视为 Humacyte 或任何其他人对 Humacyte 将在任何特定时间框架内或根本上实现其目标和计划的陈述或保证。除法律要求外，Humacyte 目前无意更新本新闻稿中的任何前瞻性声明。因此，您不应依赖这些前瞻性声明作为 Humacyte 在本新闻稿日期之后的任何日期的观点。</p>
<p><strong>Humacyte 投资者联系：</strong></p>
<p>Joyce Allaire</p>
<p>LifeSci Advisors LLC</p>
<p>+1-617-435-6602</p>
<p>jallaire@lifesciadvisors.com</p>
<p>investors@humacyte.com</p>
<p><strong>Humacyte 媒体联系：</strong></p>
<p>Rich Luchette</p>
<p>Precision Strategies</p>
<p>+1-202-845-3924</p>
<p>rich@precisionstrategies.com</p>
<p>media@humacyte.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png"/></p>

HUMA

巴克莱银行

<p>Humacyte, Inc.（纳斯达克代码：HUMA）宣布以每股 1.05 美元的价格公开发行 47,619,048 股普通股，筹集约 5000 万美元的总收入。预计交易将在 2026 年 6 月 12 日左右完成。净收入将用于 Symvess®的商业化、BLA 补充申请、管道开发和营运资金。巴克莱银行、BTIG 和 Titan Partners 为联合主承销商</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.</p>
<div class="lb-trans"><p>北卡罗来纳州达勒姆，2026 年 6 月 10 日（全球新闻稿）—— Humacyte, Inc.（纳斯达克：HUMA）是一家商业阶段的生物技术平台公司，开发可普遍植入的生物工程人类组织，今天宣布以每股 1.05 美元的公开发行价格定价 47,619,048 股普通股的承销公开发行。预计此次发行的总毛收益为 5000 万美元，未扣除 Humacyte 应支付的承销折扣和佣金及其他发行费用。此次发行的结束预计将在 2026 年 6 月 12 日左右进行，具体取决于满足惯例的结束条件。此外，Humacyte 已向承销商授予 30 天的选择权，以按公开发行价格购买最多 7,142,857 股 Humacyte 的普通股，扣除承销折扣和佣金。所有普通股均由 Humacyte 出售。</p>
</div><p>Barclays, BTIG and Titan Partners, a division of American Capital Partners, are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>巴克莱银行、BTIG 和 Titan Partners（美国资本合伙公司的一个部门）作为此次发行的联合账簿管理人。</p>
</div><p>Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess®, the planned filing of a Biologics License Application supplement in a hemodialysis indication and related activities, the development of the product candidates in its pipeline and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Humacyte 打算将其从此次发行中获得的净收益用于资助 Symvess® 的商业化、计划提交生物制品许可证申请补充的血液透析适应症及相关活动、开发其管道中的产品候选者，以及用于营运资金和一般企业用途。</p>
</div><p>A shelf registration statement on Form S-3 (No. 333-290231) was previously filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2025 and declared effective by the SEC on September 22, 2025. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on June 10, 2026 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that Humacyte has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about Humacyte and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at ProspectusDelivery@btig.com; or Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.</p>
<div class="lb-trans"><p>在 2025 年 9 月 12 日，已向证券交易委员会（“SEC”）提交了一份 S-3 表格的货架注册声明（编号 333-290231），并于 2025 年 9 月 22 日获得 SEC 的有效声明。证券是通过与此次发行相关的招股说明书补充和附带招股说明书进行发行的，这些文件构成注册声明的一部分。与此次发行相关的初步招股说明书补充及附带招股说明书已于 2026 年 6 月 10 日提交给 SEC，并可在 SEC 的网站 www.sec.gov 上获取。与此次发行相关的最终招股说明书补充及附带招股说明书将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。在投资此次发行之前，您应完整阅读与此次发行相关的每份招股说明书补充及附带招股说明书，以及 Humacyte 向 SEC 提交的其他文件，这些文件在招股说明书补充及附带招股说明书中引用，提供有关 Humacyte 和此次发行的更多信息。最终招股说明书补充的副本（可用时）及与此次发行相关的附带招股说明书可从巴克莱资本公司（Barclays Capital Inc.），邮寄地址：Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717，电话：(888) 603-5847，或通过电子邮件 barclaysprospectus@broadridge.com；BTIG, LLC，地址：65 East 55th Street, New York, New York 10022，电话：(212) 593-7555，或通过电子邮件 ProspectusDelivery@btig.com；或 Titan Partners Group LLC（美国资本合伙公司的一个部门），地址：4 World Trade Center, 49th Floor, New York, NY 10007，电话：(929) 833-1246，或通过电子邮件 prospectus@titanpartnersgrp.com 获取。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买此处所述任何证券的要约，也不应在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不符，则此类要约、招揽或销售将是非法的。</p>
</div><p><strong>About Humacyte</strong></p>
<div class="lb-trans"><p><strong>关于 Humacyte</strong></p>
</div><p>Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of Symvess, its first FDA-approved product. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.</p>
<div class="lb-trans"><p>Humacyte, Inc.（纳斯达克：HUMA）是一家商业阶段的生物技术平台公司，开发可普遍植入的生物工程人类组织，并于 2025 年第一季度开始在美国商业推出其首个 FDA 批准的产品 Symvess。Humacyte 正在开创可即用的、普遍植入的生物工程人类组织、先进组织构造和器官系统的开发与制造，旨在改善患者的生活并改变医学实践。Humacyte 正在利用其新颖、可扩展的技术平台，开发专有的生物工程无细胞人类组织，用于治疗多种解剖部位的疾病和病症，涵盖多个治疗领域。</p>
</div><p>For uses other than the U.S. Food and Drug Administration (“FDA”) approval in the extremity vascular trauma indication, the acellular tissue engineered vessel (“ATEV”) is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.</p>
<div class="lb-trans"><p>除美国食品和药物管理局（“FDA”）在肢体血管创伤适应症下的批准外，无细胞组织工程血管（“ATEV”）为一种研究性产品，尚未获得 FDA 或任何其他监管机构的销售批准。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and satisfaction of customary closing conditions of the offering and the anticipated use of proceeds from the offering. Humacyte cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended December 31, 2025 and in Humacyte’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by law, Humacyte has no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.</p>
<div class="lb-trans"><p>本新闻稿包含基于信念和假设以及当前可用信息的前瞻性声明。在某些情况下，您可以通过以下词语识别前瞻性声明：“可能”、“将”、“能够”、“会”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“正在进行” 或这些术语的否定形式或其他可比术语，尽管并非所有前瞻性声明都包含这些词。这些声明涉及风险、不确定性和其他因素，可能导致实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的信息有实质性差异。尽管 Humacyte 相信其对本新闻稿中每个前瞻性声明都有合理的依据，但 Humacyte 提醒您，这些声明是基于其当前已知的事实和因素的组合以及对未来的预测，Humacyte 对此无法确定。本新闻稿中的前瞻性声明包括但不限于关于发行的惯常成交条件的时间和满足情况以及预计的发行收益使用情况的声明。Humacyte 无法保证本新闻稿中的前瞻性声明将被证明是准确的。这些前瞻性声明受到许多重大风险和不确定性的影响，这些风险和不确定性可能导致实际结果与预期结果有实质性差异，包括但不限于适用法律或法规的变化，Humacyte 可能受到其他经济、商业和/或竞争因素的不利影响的可能性，以及其他风险和不确定性，包括在 Humacyte 截至 2025 年 12 月 31 日的年度报告 Form 10-K 和截至 2026 年 3 月 31 日的季度报告 Form 10-Q 中描述的 “风险因素” 标题下的风险，这些报告均已由 Humacyte 提交给 SEC，以及未来的 SEC 文件。这些因素大多数超出了 Humacyte 的控制范围，且难以预测。此外，如果前瞻性声明被证明不准确，则不准确性可能是实质性的。鉴于这些前瞻性声明中的重大不确定性，您不应将这些声明视为 Humacyte 或任何其他人对 Humacyte 将在任何特定时间框架内或根本上实现其目标和计划的陈述或保证。除法律要求外，Humacyte 目前无意更新本新闻稿中的任何前瞻性声明。因此，您不应依赖这些前瞻性声明作为 Humacyte 在本新闻稿日期之后的任何日期的观点。</p>
</div><p><strong>Humacyte Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>Humacyte 投资者联系：</strong></p>
</div><p>Joyce Allaire</p>
<div class="lb-trans"><p>Joyce Allaire</p>
</div><p>LifeSci Advisors LLC</p>
<div class="lb-trans"><p>LifeSci Advisors LLC</p>
</div><p>+1-617-435-6602</p>
<div class="lb-trans"><p>+1-617-435-6602</p>
</div><p>jallaire@lifesciadvisors.com</p>
<div class="lb-trans"><p>jallaire@lifesciadvisors.com</p>
</div><p>investors@humacyte.com</p>
<div class="lb-trans"><p>investors@humacyte.com</p>
</div><p><strong>Humacyte Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Humacyte 媒体联系：</strong></p>
</div><p>Rich Luchette</p>
<div class="lb-trans"><p>Rich Luchette</p>
</div><p>Precision Strategies</p>
<div class="lb-trans"><p>Precision Strategies</p>
</div><p>+1-202-845-3924</p>
<div class="lb-trans"><p>+1-202-845-3924</p>
</div><p>rich@precisionstrategies.com</p>
<div class="lb-trans"><p>rich@precisionstrategies.com</p>
</div><p>media@humacyte.com</p>
<div class="lb-trans"><p>media@humacyte.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTczNTM1NiM3NjU2OTUwIzIyMDk0MzY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png"/></p>

Humacyte, Inc. 宣布其普通股公开发行的定价 | HUMA 股票新闻